GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » PEG Ratio

Calithera Biosciences (Calithera Biosciences) PEG Ratio : N/A (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Calithera Biosciences's PE Ratio without NRI is 0.00. Calithera Biosciences's 5-Year EBITDA growth rate is 0.00%. Therefore, Calithera Biosciences's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Calithera Biosciences's PEG Ratio or its related term are showing as below:



CALA's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.535
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Calithera Biosciences PEG Ratio Historical Data

The historical data trend for Calithera Biosciences's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences PEG Ratio Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calithera Biosciences's PEG Ratio

For the Biotechnology subindustry, Calithera Biosciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's PEG Ratio falls into.



Calithera Biosciences PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Calithera Biosciences's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Calithera Biosciences  (OTCPK:CALA) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Calithera Biosciences PEG Ratio Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Calithera Biosciences (Calithera Biosciences) Headlines